didanosine and Neoplasms

didanosine has been researched along with Neoplasms* in 4 studies

Reviews

2 review(s) available for didanosine and Neoplasms

ArticleYear
Antiretroviral agents.
    IARC monographs on the evaluation of carcinogenic risks to humans, 2000, Volume: 76

    Topics: Acyclovir; Animals; Antiviral Agents; Carcinogens; Didanosine; Disease Models, Animal; Evidence-Based Medicine; Humans; Intestinal Absorption; Neoplasms; Risk Factors; Tissue Distribution; Zalcitabine; Zidovudine

2000
Pediatric human immunodeficiency virus infection.
    Clinical microbiology reviews, 1996, Volume: 9, Issue:4

    In the past decade, an increase in pediatric human immunodeficiency virus (HIV) infection has had a substantial impact on childhood morbidity and mortality worldwide. The vertical transmission of HIV from mother to infant accounts for the vast majority of these cases. Identification of HIV-infected pregnant women needs to be impoved so that appropriate therapy can be initiated for both mothers and infants. While recent data demonstrate a dramatic decrease in HIV transmission from a subset of women treated with zidovudine during pregnancy, further efforts at reducing transmission are desperately needed. This review focuses on vertically transmitted HIV infection in children, its epidemiology, diagnostic criteria, natural history, and clinical manifestations including infectious and noninfectious complications. An overview of the complex medical management of these children ensues, including the use of antiretroviral therapy. Opportunistic infection prophylaxis is reviewed, along with the important role of other supportive therapies.

    Topics: AIDS-Related Opportunistic Infections; Anti-HIV Agents; Central Nervous System Diseases; Child; Child, Preschool; Cytomegalovirus Infections; Didanosine; Disease Transmission, Infectious; Eye Diseases; Female; Gastrointestinal Diseases; Heart Diseases; Hematologic Diseases; Herpes Simplex; Herpes Zoster; HIV Infections; Humans; Incidence; Infant; Infant, Newborn; Infectious Disease Transmission, Vertical; Kidney Diseases; Male; Neoplasms; Pregnancy; Prevalence; Risk Factors; Sexual Behavior; Skin Diseases; Transfusion Reaction; Zidovudine

1996

Other Studies

2 other study(ies) available for didanosine and Neoplasms

ArticleYear
Risk of cancer in children exposed to antiretroviral nucleoside analogues in utero: The french experience.
    Environmental and molecular mutagenesis, 2019, Volume: 60, Issue:5

    All nucleoside analogues for treating HIV infection, due to their capacity to integrate into and alter human DNA, are experimentally genotoxic to some extent. The long-term oncogenic risk after in utero exposure remains to be determined. Cancer incidence in uninfected children exposed to nucleos(t)ide reverse transcriptase inhibitors (NRTIs) was evaluated, by cross-checking against the National Cancer Registry, in the French perinatal study of children born to HIV

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Didanosine; Female; HIV Infections; Humans; Incidence; Infant; Infant, Newborn; Male; Maternal Exposure; Maternal-Fetal Exchange; Neoplasms; Nucleosides; Pregnancy; Prenatal Exposure Delayed Effects; Prospective Studies; Reverse Transcriptase Inhibitors; Risk; Surveys and Questionnaires; Zidovudine

2019
Risk of cancer in children exposed to didanosine in utero.
    AIDS (London, England), 2016, 05-15, Volume: 30, Issue:8

    Evaluation of long-term tolerance to antiretroviral exposure during pregnancy is required. An increased risk of cancer has been suggested in children exposed in utero to didanosine.. Updated evaluation of cancer incidence in uninfected children exposed to nucleos(t)ide reverse transcriptase inhibitors (NRTIs) in the French perinatal study of children born to HIV+ mothers, by cross-checking with the National Cancer Registry. Associations between cancer risk and exposure to NRTIs were evaluated by univariate survival analysis and Cox proportional hazard models. Standardized incidence ratios (SIR) were used for comparison with the general population.. A total of 21 cancers were identified in 15 163 children (median age: 9.9 years [interquartile range (IQR): 5.8-14.2]) exposed to at least one NRTI in utero, between 1990 and 2014. Five children were exposed to zidovudine monotherapy, and 16 to various combinations, seven including didanosine. Didanosine accounted for only 10% of prescriptions but was associated with one-third of cancers. In a multivariate analysis, didanosine exposure was significantly associated with higher risk [hazard ratio = 3.0 (0.9-9.8)]. The risk was specifically linked with first-trimester exposure [hazard ratio = 5.5 (2.1-14.4)]. Overall, the total number of cases was not significantly different from that expected for the general population [SIR = 0.8 (0.47-1.24)], but was twice that expected after didanosine exposure [SIR = 2.5 (1.01-5.19)].. There are strong arguments to suggest that didanosine displays transplacental oncogenicity. Although not extrapolable to other NRTIs, they stress the need for comprehensive evaluation of the transplacental genotoxicity of this antiretroviral class.

    Topics: Adolescent; Anti-HIV Agents; Child; Child, Preschool; Didanosine; Female; France; HIV Infections; Humans; Incidence; Infant; Infant, Newborn; Maternal-Fetal Exchange; Neoplasms; Pregnancy; Pregnancy Complications, Infectious; Prenatal Exposure Delayed Effects; Prospective Studies; Risk Assessment; Surveys and Questionnaires

2016